de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.
Google Scholar
Niu X, You Q, Hou K, Tian Y, Wei P, Zhu Y, et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist Update. 2025;78:101170.
Google Scholar
Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41:1257–74.
Google Scholar
Wang Y, Patti GJ. The Warburg effect: a signature of mitochondrial overload. Trends Cell Biol. 2023;33:1014–20.
Google Scholar
Zhong X, He X, Wang Y, Hu Z, Huang H, Zhao S, et al. Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. J Hematol Oncol. 2022;15:160.
Google Scholar
Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17:6.
Google Scholar
Kooshan Z, Cárdenas-Piedra L, Clements J, Batra J. Glycolysis, the sweet appetite of the tumor microenvironment. Cancer Lett. 2024;600:217156.
Google Scholar
DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018;9:446.
Google Scholar
Feng Y, Chen Y, Wu X, Chen J, Zhou Q, Liu B, et al. Interplay of energy metabolism and autophagy. Autophagy. 2024;20:4–14.
Google Scholar
Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int J Biol Sci. 2024;20:3113–25.
Google Scholar
Nishimura S, Linares JF, L’Hermitte A, Duran A, Cid-Diaz T, Martinez-Ordonez A, et al. Opposing regulation of the STING pathway in hepatic stellate cells by NBR1 and p62 determines the progression of hepatocellular carcinoma. Mol Cell. 2024;84:4660–.e10.
Google Scholar
Tang J, Li J, Lian J, Huang Y, Zhang Y, Lu Y, et al. CDK2-activated TRIM32 phosphorylation and nuclear translocation promote radioresistance in triple-negative breast cancer. J Adv Res. 2024;61:239–51.
Google Scholar
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer. 2024;23:148.
Google Scholar
Mattiroli F, Penengo L. Histone ubiquitination: an integrative signaling platform in genome stability. Trends Genet. 2021;37:566–81.
Google Scholar
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
Google Scholar
Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–33.
Google Scholar
Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399–434.
Google Scholar
Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129–57.
Google Scholar
Wang P, Dai X, Jiang W, Li Y, Wei W. RBR E3 ubiquitin ligases in tumorigenesis. Semin Cancer Biol. 2020;67:131–44.
Google Scholar
Duan S, Pagano M. Ubiquitin ligases in cancer: functions and clinical potentials. Cell Chem Biol. 2021;28:918–33.
Google Scholar
Ebadi P, Stratton CM, Olsen SK. E3 ubiquitin ligases in signaling, disease, and therapeutics. Trends Biochem Sci. 2025;50:960–76.
Google Scholar
Chen S, Leng P, Guo J, Zhou H. FBXW7 in breast cancer: mechanism of action and therapeutic potential. J Exp Clin Cancer Res. 2023;42:226.
Google Scholar
Wang Z, Wang MM, Geng Y, Ye CY, Zang YS. Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer. J Transl Med. 2022;20:402.
Google Scholar
Frosk P, Weiler T, Nylen E, Sudha T, Greenberg CR, Morgan K, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet. 2002;70:663–72.
Google Scholar
Locke M, Tinsley CL, Benson MA, Blake DJ. TRIM32 is an E3 ubiquitin ligase for dysbindin. Hum Mol Genet. 2009;18:2344–58.
Google Scholar
Goyani S, Shinde A, Shukla S, Saranga MV, Currim F, Mane M, et al. Enhanced translocation of TRIM32 to mitochondria sensitizes dopaminergic neuronal cells to apoptosis during stress conditions in Parkinson’s disease. Febs J. 2024;291:2636–55.
Google Scholar
Zhou X, Zhao Y, Huang S, Shu H, Zhang Y, Yang H, et al. TRIM32 promotes neuronal ferroptosis by enhancing K63-linked ubiquitination and subsequent p62-selective autophagic degradation of GPX4. Int J Biol Sci. 2025;21:1259–74.
Google Scholar
Xu J, Liu W, Chen L, Zhang J, Zhang D, Huang X, et al. TRIM32 promotes anoikis resistance and metastasis in NSCLC by degrading CHEK2 to enhance IL-6 secretion. Cell Death Differ. 2026;33:126–39.
Ma Y, Zhang H, Chen C, Liu L, Ding T, Wang Y, et al. TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer. Oncogene. 2022;41:1589–99.
Google Scholar
Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 2014;21:1792–804.
Google Scholar
Zhao M, Song K, Hao W, Wang L, Patil G, Li Q, et al. Non-proteolytic ubiquitination of OTULIN regulates the NF-κB signaling pathway. J Mol Cell Biol. 2020;12:163–75.
Google Scholar
Chu M, Shi X, Shi Z, Liang Y. PLAAT2 suppresses gastric cancer progression by facilitating cMyc ubiquitination and inhibiting MEK/ERK signaling. Cell Death Dis. 2026;17:314.
Wang L, Song YY, Wang Y, Liu XX, Yin YL, Gao S, et al. RHBDF1 deficiency suppresses melanoma glycolysis and enhances the efficacy of immunotherapy by facilitating glucose-6-phosphate isomerase degradation via TRIM32. Pharm Res. 2023;198:106995.
Google Scholar
Huang N, Sun X, Li P, Liu X, Zhang X, Chen Q, et al. TRIM family contributes to tumorigenesis, cancer development, and drug resistance. Exp Hematol Oncol. 2022;11:75.
Google Scholar
Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21:501–21.
Google Scholar
Dvorkin S, Cambier S, Volkman HE, Stetson DB. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57:718–30.
Google Scholar
Sun Y, Patterson-Fortin J, Han S, Li Z, Nowicka Z, Hirohashi Y, et al. 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer. Nat Commun. 2024;15:6676.
Google Scholar
Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425–44.
Google Scholar
Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136.
Google Scholar
Zhang B, Xu P, Ablasser A. Regulation of the cGAS-STING pathway. Annu Rev Immunol. 2025;43:667–92.
Google Scholar
Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3:1452–63.
Google Scholar
Liao K, Wen J, Liu Z, Zhang B, Zhang X, Fu Y, et al. The role of the intratumoral microbiome in the occurrence, proliferation, and metastasis of colorectal cancer and its underlying therapeutic strategies. Ageing Res Rev. 2025;111:102820.
Google Scholar
Mahin J, Xu X, Li L, Zhang C. cGAS/STING in skin melanoma: from molecular mechanisms to therapeutics. Cell Commun Signal. 2024;22:553.
Google Scholar
Chou WC, Rampanelli E, Li X, Ting JP. Impact of intracellular innate immune receptors on immunometabolism. Cell Mol Immunol. 2022;19:337–51.
Google Scholar
Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of the DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmacol Sin B. 2021;11:2983–94.
Google Scholar
Sacristán Santos V, Pensado-López A, García-Campelo R, Antolín Novoa S, Señaris Rodríguez R, Andón FT. Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy in hormone-dependent cancers. J Immunother Cancer. 2025;13:e010950.
Wu Y, Lu WM, Cui QR, Zhou J, Lu GD. Metabolic regulation of cGAS-STING signaling in the tumor microenvironment: dual immune roles and therapeutic implications. Cytokine Growth Factor Rev. 2025;85:43–55.
Blaha CS, Ramakrishnan G, Jeon SM, Nogueira V, Rho H, Kang S, et al. A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis. Nat Commun. 2022;13:899.
Google Scholar
Harris B, Saleem S, Cook N, Searle E. Targeting hypoxia in solid and haematological malignancies. J Exp Clin Cancer Res. 2022;41:318.
Google Scholar
Haloi N, Wen PC, Cheng Q, Yang M, Natarajan G, Camara AKS, et al. Structural basis of complex formation between mitochondrial anion channel VDAC1 and Hexokinase-II. Commun Biol. 2021;4:667.
Google Scholar
Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277:7610–8.
Google Scholar
Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 2022;34:1312–.e6.
Google Scholar
Wang J, Huang Q, Hu X, Zhang S, Jiang Y, Yao G, et al. Disrupting circadian rhythm via the PER1-HK2 axis reverses trastuzumab resistance in gastric cancer. Cancer Res. 2022;82:1503–17.
Google Scholar
Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun. 2021;12:1812.
Google Scholar
Xue M, Dong L, Zhang H, Li Y, Qiu K, Zhao Z, et al. METTL16 promotes liver cancer stem cell self-renewal by controlling ribosome biogenesis and mRNA translation. J Hematol Oncol. 2024;17:7.
Google Scholar
Ooshio T, Yamamoto M, Fujii K, Xin B, Watanabe K, Goto M, et al. Hepatocyte mitogen-activated protein kinase kinase 7 contributes to the restoration of the liver parenchyma following injury in mice. Hepatology. 2021;73:2510–26.
Google Scholar
Bu W, Sun X, Xue X, Geng S, Yang T, Zhang J, et al. Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment. Hepatology. 2025;81:491–508.
Google Scholar
Zhang L, Jiang C, Zhong Y, Sun K, Jing H, Song J, et al. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 2023;25:1208–22.
Google Scholar
Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J, et al. Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharmacol Sin B. 2024;14:953–1008.
Google Scholar
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.
Google Scholar
Chen X, Wu H, Liu Y, Liu L, Houser SR, Wang WE. Metabolic reprogramming: A by-product or a driver of cardiomyocyte proliferation? Circulation. 2024;149:1598–610.
Google Scholar
Horn P, Tacke F. Metabolic reprogramming in liver fibrosis. Cell Metab. 2024;36:1439–55.
Google Scholar
Kanasaki K. The aberrant glycolysis in the kidney proximal tubule: potential therapeutic target for DKD. Kidney Int. 2023;104:1056–9.
Google Scholar
Humphreys LM, Smith P, Chen Z, Fouad S, D’Angiolella V. The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death Differ. 2021;28:522–37.
Google Scholar
Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L, et al. Clinical significance of FBXW7 loss of function in human cancers. Mol Cancer. 2022;21:87.
Google Scholar
Xu Q, Hua X, Li B, Jiang B, Jin J, Wu R, et al. Intrinsic STING of CD8 + T cells regulates self-metabolic reprogramming and memory to exert anti-tumor effects. Cell Commun Signal. 2025;23:99.
Google Scholar
Yao H, Wang S, Zhou X, Sun J, Zhou G, Zhou D, et al. STING promotes proliferation and induces drug resistance in colorectal cancer by regulating the AMPK-mTOR pathway. J Gastrointest Oncol. 2022;13:2458–71.
Google Scholar
Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: acting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248–57.
Google Scholar
